Magle Chemoswed Holding Past Earnings Performance
Past criteria checks 0/6
Magle Chemoswed Holding's earnings have been declining at an average annual rate of -19.5%, while the Life Sciences industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 17.1% per year.
Key information
-19.52%
Earnings growth rate
-13.91%
EPS growth rate
| Life Sciences Industry Growth | 31.84% |
| Revenue growth rate | 17.05% |
| Return on equity | -5.00% |
| Net Margin | -8.85% |
| Next Earnings Update | 27 Feb 2026 |
Recent past performance updates
Recent updates
Market Cool On Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Revenues Pushing Shares 28% Lower
Jan 27
Health Check: How Prudently Does Magle Chemoswed Holding (STO:MAGLE) Use Debt?
Jan 23Sentiment Still Eluding Magle Chemoswed Holding AB (publ) (STO:MAGLE)
Nov 21Investors Give Magle Chemoswed Holding AB (publ) (STO:MAGLE) Shares A 26% Hiding
Aug 12The Magle Chemoswed Holding AB (publ) (STO:MAGLE) Analyst Just Cut Their Revenue Forecast By 10%
Aug 04Here's Why Magle Chemoswed Holding (STO:MAGLE) Has Caught The Eye Of Investors
Feb 28Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Share Price Matching Investor Opinion
Jan 03Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem
Nov 04Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher
Jun 26Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet
Jun 19Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Revenue & Expenses Breakdown
How Magle Chemoswed Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 25 | 300 | -27 | 246 | 0 |
| 30 Jun 25 | 292 | -20 | 233 | 0 |
| 31 Mar 25 | 285 | 8 | 201 | 0 |
| 31 Dec 24 | 241 | 12 | 177 | 0 |
| 30 Sep 24 | 209 | 17 | 155 | 0 |
| 30 Jun 24 | 179 | 8 | 138 | 0 |
| 31 Mar 24 | 171 | 12 | 132 | 0 |
| 31 Dec 23 | 171 | 12 | 131 | 0 |
| 30 Sep 23 | 160 | 8 | 124 | 0 |
| 30 Jun 23 | 158 | 9 | 121 | 0 |
| 31 Mar 23 | 155 | 8 | 120 | 0 |
| 31 Dec 22 | 148 | 9 | 113 | 0 |
| 30 Sep 22 | 138 | 10 | 106 | 0 |
| 30 Jun 22 | 136 | 10 | 108 | 0 |
| 31 Mar 22 | 133 | 7 | 106 | 0 |
| 31 Dec 21 | 132 | 4 | 106 | 0 |
| 30 Sep 21 | 137 | 3 | 105 | 0 |
| 30 Jun 21 | 133 | 1 | 99 | 0 |
| 31 Mar 21 | 134 | 2 | 99 | 0 |
| 31 Dec 20 | 142 | 2 | 100 | 0 |
| 30 Sep 20 | 151 | 14 | 103 | 0 |
| 30 Jun 20 | 140 | 8 | 104 | 0 |
| 31 Mar 20 | 137 | 1 | 100 | 0 |
| 31 Dec 19 | 132 | 1 | 96 | 0 |
| 31 Dec 18 | 110 | -3 | 99 | 0 |
Quality Earnings: MAGLE is currently unprofitable.
Growing Profit Margin: MAGLE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MAGLE is unprofitable, and losses have increased over the past 5 years at a rate of 19.5% per year.
Accelerating Growth: Unable to compare MAGLE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MAGLE is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.7%).
Return on Equity
High ROE: MAGLE has a negative Return on Equity (-5%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/09 08:49 |
| End of Day Share Price | 2026/02/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Magle Chemoswed Holding AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |